ARTICLE | Company News
Eolas, AstraZeneca deal
August 3, 2015 7:00 AM UTC
Eolas granted AstraZeneca exclusive, worldwide rights to develop and commercialize an orexin 1 receptor ( HCRTR1; OX1R) antagonist program, which is in preclinical testing for smoking cessation. Eol...